+ Watch PPHM
on My Watchlist
A biopharmaceutical company with a portfolio of clinical stage and pre-clinical product candidates using monoclonal antibodies for the treatment of cancer and viral diseases.
A speculator's dream date. This stock recently suffered a tremendous loss due to the negligent actions of a third party contractor. The speculation that this company's new cancer durg, now in phase III, will be successful still remains strong. The speculation is bolstered by the positive results of the phase II trial that shows their cancer drug helping people live twice as long as competitors drugs. People now buying into this stock at this historically low level are betting that the mixup between placebos and the actual drug in phase II resulted in a lower overall success rate of the drug fighting cancer and that positive phase III testing results will launch the price well beyond the $5.50 level it recently fell from. The investors that got burned holding on to shares near or at the $5.50 level may never come back, but new speculators with cooler heads and looking for a bargain will buy, hold and push this to newer highs.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions